Atlas Trials

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Clinical trial NCT03472027 · COMPLETED

Trial details

NCT number
NCT03472027
Sponsor
Biocad
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma
Start date
2017-10-02
Primary completion
2018-09-11
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.